Physician profile
Devin Ericson
NPI 1245850619
$1,756.60
in general payments reported to CMS, 2019-2025
21 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $19.55 · 2024: $452 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $353.54 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $265.99 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $163.95 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $109.24 | 2024-2025 | Cologuard Collection Kit |
| Alkermes, INC. | $101.04 | 2021 | |
| Amgen INC. | $98.00 | 2024-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $91.35 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $82.65 | 2024-2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $80.95 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $71.16 | 2024-2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.72 | 2024-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $51.16 | 2025 | |
| Novartis Pharmaceuticals Corporation | $40.41 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $33.70 | 2025 | Voquezna |
| Corcept Therapeutics | $29.02 | 2024 | Korlym |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $25.57 | 2025 | Auvelity |
| Biotronik Nro, INC. | $20.69 | 2025 | Prospera |
| Eisai INC. | $20.30 | 2025 | |
| Genzyme Corporation | $19.55 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.65 | 2025 | Zoryve |
| Lundbeck LLC | $15.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Ericson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.